Since 1981, GnRH agonist administration has been the treatment of choice for central precocious puberty. Continuous administration of the agonist, instead of permanently stimulating gonadotropin secretion, deeply suppresses LH and FSH levels and induces a marked inhibition of gonadal activity and regression of clinical symptoms. This inhibitory effect is due both to specific kinetic parameters ...

Abstract Study question Is patients’ BMI associated with oocyte yield and maturation following different trigger strategies r-hCG, GnRH agonist (GnRHa) or dual trigger? Summary answer Patients’ is not triggering rhCG, GnRHa trigger. What known already Triggering final a key step of ovarian stimulation for IVF/ICSI treatment. Although hCG has traditionally been the gold standard maturation, incr...

Substitution at positions 6 and 10 can result in super-active peptides. Therefore, several LHRH analogues substituted at position 6, 10, or both are much more active than LHRH and have prolonged activity [5]. Of these analogues, the most important are [D-Trp 6 ]LHRH (triptorelin), [D-Leu 6 ,Pro 9 NHET]LHRH (leuprolide), [D-Ser(Bu t ) 6 ,Pro 9 NHET]LHRH (buserelin), and [D-Ser(Bu t ) 6 ,AzaGly 1...

Background and objectives: Prostate cancer is the second leading cause of mortality among men worldwide, and the eighth cancer-related cause of death in Iran. Male sex hormones (androgens) are the main cause of prostate cancer cells. Triptorelin is considered a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) in the treatment of prostate cancer. This study aimed to evalua...

PURPOSE Long-acting gonadotropin-releasing hormone agonists (GnRHa) are commonly used to treat central precocious puberty (CPP) in Korea. Although rare, there have been reports on the characteristic of adverse reactions of GnRHa in CPP among the Korean population. This study was intended to report on our clinical experience regarding significant adverse reactions to long-acting GnRHa in CPP and...

BACKGROUND Androgen deprivation therapy has been associated with worsened body image in prostate cancer patients. Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer. OBJECTIVE The aim was to evaluate the changes in self-perception of...